← All trials
NCT07300670
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2026
- Primary completion
- Apr 30, 2026
- Completion date
- Apr 30, 2026
- First posted
- Dec 24, 2025
- Last posted
- Dec 24, 2025
- Enrollment
- 12
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of TurkuLead sponsor
- University of HelsinkiCollaborator
- University of TurkuCollaborator
- University of TurkuSponsor investigator
- University of HelsinkiCollaborator
- University of TurkuCollaborator
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.